Antiangiogenic effects of somatostatin analogues

Clinical Endocrinology

Volumn 57, Issue 4, 2002, Pages 425-441

  Garcia De La Torre N ^a   Wass, J A H ^a   Turner, H E ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; MESSENGER RNA; OCTREOTIDE; PTR 3173; RECEPTOR SUBTYPE; SEGLITIDE; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TIROFIBAN; UNCLASSIFIED DRUG; VAPREOTIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; CHEMOTAXIS; DRUG EFFECT; DRUG EFFICACY; ENDOCRINE TUMOR; ENDOTHELIUM CELL; HUMAN; MONOCYTE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR AFFINITY; REVIEW;

ANGIOGENESIS INHIBITORS; DIABETIC NEPHROPATHIES; ENDOCRINE GLAND NEOPLASMS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RETINAL NEOVASCULARIZATION; SOMATOSTATIN;

EID: 0036401087     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2002.01619.x     Document Type: Review

References (177)

1. Adamis, A.P., Shima, D.T., Yeo, K.T., Yeo, T.K., Brown, L.F., Berse, B., D'Amore, P.A. & Folkman, J. (1993) Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochemical and Biophysical Research Communications, 193, 631-638.
2. Aiello, L.P., Avery, R.L., Arrigg, P.G., Keyt, B.A., Jampel, H.D., Shah, S.T., Pasquale, L.R., Thieme, H., Iwamoto, M.A. & Park, J.E. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine, 331, 1480-1487.
3. Ain, K.B., Taylor, K.D., Tofiq, S. & Venkataraman, G. (1997) Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. Journal of Clinical Endocrinology and Metabolism, 82, 1857-1862.
4. Akslen, L.A. & Livolsi, V.A. (2000) Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Human Pathology, 31, 439-442.
5. Albini, A., Florio, T., Giunciuglio, D., Masiello, L., Carlone, S., Corsaro, A., Thellung, S., Cai, T., Noonan, D.M. & Schettini, G. (1999) Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB Journal, 13, 647-655.
6. Averbukh, E., Halpert, M., Yanko, R., Yanko, L., Peer, J., Levinger, S., Flyvberg, A. & Raz, I. (2000) Octreotide, a somatostatin analogue, fails to inhibit hypoxia-induced retinal neovascularization in the neonatal rat. International Journal of Experimental Diabetes Research, 11, 39-47.
7. Bak, M., Thomsen, K. & Flyvbjerg, A. (2001) Effects of the somatostatin analogue octreotide on renal function in conscious diabetic rats. Nephrology, Dialysis and Transplantation, 16, 2002-2007.
8. Balster, D.A., O'Dorisio, M.S., Summers, M.A. & Turman, M.D. (2001) Segmental expression of somatostatin receptor subtypes sst1 and sst2 in tubules and glomeruli of human kidney. American Journal of Physiology and Renal Physiology, 280, F457-F465.
9. Barreca, A., Cariola, G., Ponzani, P., Arvigo, M., Foppiani, L., Giordano, G. & Minuto, F. (1995) Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex. Clinical Endocrinology, 42, 161-167.
10. Barrie, R., Woltering, E.A., Harjarizadeh, H., Mueller, C., Ure, T. & Fletcher, W.S. (1993) Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. Journal of Surgical Research, 55, 446-450.
11. Bensaid, M., Tahiri-Jouti, N., Cambillau, C., Vigurie, N., Colas, B., Vidal, C., Tauber, J.P., Esteve, J.P., Susini, C. & Vaysse, N. (1992) Basic fibroblast growth factor induces proliferation of a rat pancreatic cancer cell line. Inhibition by somatostatin. International Journal of Cancer, 50, 796-799.
12. Bloom, S.R., Mortimer, C.H., Thorner, M.O., Besser, G.M., Hall, R., Gomez Pan, A., Roy, V.M., Russell, R.C., Coy, D.H., Kastin, A.J. & Schally, A.V. (1974) Inhibition of gastrin and gastric-acid secretion by growth hormone release-inhibiting hormone. Lancet, 2, 1106-1109.
13. Bochner, B.H., Cote, R.J., Weidner, N., Groshen, S., Chen, S.C., Skinner, D.G. & Nichols, P.W. (1995) Angiogenesis in bladder cancer: relationship between microvessel density and tumour prognosis. Journal of the National Cancer Institute, 87, 1603-1612.
14. Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J. & Guillemin, R. (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science, 179, 77-79.
15. Breder, C.D., Yamada, Y., Yasuda, K., Seino, S., Saper, C.B. & Bell, G.I. (1992) Differential expression of somatostatin receptor subtypes in brain. Journal of Neuroscience, 12, 3920-3934.
16. Brem, S.S., Gullino, P.M. & Medina, D. (1977) Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science, 195, 880-881.
17. Brown, L.F., Berse, B., Jackman, R.W., Tognazzi, K., Guidi, A.J., Dvorak, H.F., Senger, D.R., Connolly, J.L. & Schnitt, S.J. (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Pathology, 26, 86-91.
18. Bruno, J.F., Xu, Y., Song, J. & Berelowitz, M. (1993) Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. Endocrinology, 133, 2561-2567.
19. Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G. & Weckbecker, G. (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology, 146, 707-716.
20. Burgos, R., Mateo, C., Canton, A., Hernandez, C., Mesa, J. & Simo, R. (2000) Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy. Diabetes Care, 23, 80-83.
21. Burgos, R., Simo, R., Audi, L., Mateo, C., Mesa, J., Garcia-Ramirez, M. & Carrascosa, A. (1997) Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia, 40, 1107-1109.
22. Busto, R., Carrero, I., Zapata, P., Colas, B. & Prieto, J.C. (2000) Multiple regulation of adenyl cyclase activity by G-protein coupled receptors in human foetal lung fibroblasts. Regulatory Peptides, 95, 53-58.
23. Canfield, A.E. & Schor, A.M. (1995) Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. Journal of Cell Science, 108, 797-809.
24. Cascinu, S., Del Ferro, E., Ligi, M., Staccioli, M.P., Giordani, P., Catalano, V., Agostinelli, R., Muretto, P. & Catalano, G. (2001) Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Investigation, 19, 8-12.
25. Clauss, M., Gerlach, M., Gerlach, H., Brett, J., Wang, F., Familletti, P.C., Pan, Y.C., Olander, J.V., Connolly, D.T. & Stern, D. (1990) Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. Journal of Experimental Medicine, 172, 1535-1545.
26. Colas, B., Valencia, A.M., Prieto, J.C. & Arilla, E. (1992) Somatostatin binding and modulation of adenylate cyclase in ovine retina membranes. Molecular and Cellular Endocrinology, 88, 111-117.
27. Colville-Nash, P.R. & Scott, D.L. (1992) Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Annals of the Rheumatic Diseases, 51, 919-925.
28. Cooper, M.E., Vranes, D., Youssef, S., Stacker, S.A., Cox, A.J., Rizkalla, B., Casley, D.J., Bach, L.A., Kelly, D.J. & Gilbert, R.E. (1999) Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes, 48, 2229-2239.
29. Curtis, S.B., Hewitt, J., Yakubovitz, S., Anzarut, A., Hsiang, Y.N. & Buchan, A.M.J. (2000) Somatostatin receptor subtype expression and function in human vascular tissue. American Journal of Physiology and Heart Circulation Physiology, 278, H1815-H1822.
30. D'Adda, T., Amorosi, A., Bussolati, G., Brandi, M.L. & Bordi, C. (1993) Proliferation of endothelial component of parathyroid gland in multiple endocrine neoplasia type 1. Potential relationship with a mitogenic factor. American Journal of Pathology, 143, 612-617.
31. Danesi, R., Agen, C., Benelli, U., Paolo, A.D., Nardini, D., Bocci, G., Basolo, F., Campagni, A. & Tacca, M.D. (1997) Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clinical Cancer Research, 3, 265-272.
32. Danesi, R. & Del Tacca, M. (1996) The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism, 45 (Suppl. 1), 49-50.
33. Dasgupta, P. & Mukherjee, R. (2000) Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro. British Journal of Pharmacology, 129, 101-109.
34. De Vriese, A.S., Tilton, R.G., Elger, M., Stephan, C.C., Kriz, W. & Lameire, N.H. (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. Journal of the American Society of Nephrology, 12, 993-1000.
35. Deghenghi, R., Avallone, R., Torsello, A., Muccioli, G., Ghigo, E. & Locatelli, V. (2001) Growth hormone-inhibiting activity of cortistatin in the rat. Journal of Endocrinological Investigation, 24, RC31-33.
36. Denhart, B.C., Guidi, A.J., Tognazzi, K., Dvorak, H.F. & Brown, L.F. (1997) Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Laboratory Investigation, 77, 659-664.
37. Dills, D.G., Moss, S.E., Klein, R. & Klein, B.E. (1991) Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes, 40, 1725-1730.
38. Elliot, D.E., Blum, A.M., Li, J., Metwali, A. & Weinstock, J.V. (1998) Preprosomatostatin messenger RNA is expressed by inflammatory cells and induced by inflammatory mediators and cytokines. Journal of Immunology, 160, 3997-4003.
39. Emanuelsson, H., Beatt, K.J., Bagger, J.P., Balcon, R., Heikkila, J., Piessens, J., Schaeffer, M., Suryapranata, H. & Foegh, M. (1995) Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. European Angiopeptin Study Group. Circulation, 91, 1689-1696.
40. Endo, T., Saito, T., Uchida, T. & Onaya, T. (1988) Effects of somatostatin and serotonin on calcitonin secretion from cultured rat parafollicular cells. Acta Endocrinologica, 117, 214-218.
41. Epelbaum, J. (1986) Somatostatin in the central nervous system: physiology and pathological modifications. Progress in Neurobiology, 27, 63-100.
42. Epelbaum, J., Dournaud, P., Fodor, M. & Viollet, C. (1994) The neurobiology of somatostatin. Critical Reviews in Neurobiology, 8, 25-44.
43. Eriksen, U.H., Amtorp, O., Bagger, J.P., Emanuelsson, H., Foegh, M., Henningsen, P., Saunamaki, K., Schaeffer, M., Thayssen, P. & Orskov, H. (1995) Randomized double-blind Scandinavian trial of angiopeptin versus placebo for the prevention of clinical events and restenosis after coronary balloon angioplasty. American Heart Journal, 130, 1-8.
44. Esser, S., Wolburg, K., Wolburg, H., Breier, G., Kurzchalia, T. & Risau, W. (1998) Vascular endothelial growth factor induces endothelial fenestrations in vitro. Journal of Cell Biology, 140, 947-959.
45. Ferjoux, G., Bousquet, C., Cordelier, P., Benali, N., Lopez, F., Rochaix, P., Buscail, L. & Susini, C. (2000) Signal transduction of somatostatin receptors negatively controlling cell proliferation. Journal of Physiology (Paris), 94, 205-210.
46. Ferone, D., Van Hagen, M.P., Kwekkeboom, D.J., Van Koetsveld, P.M., Mooy, D.M., Lichtenauer-Kaligis, E., Schonbrunn, A., Colao, A., Lamberts, S.W.J. & Hofland, L.J. (2000b) Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. Journal of Clinical Endocrinology and Metabolism, 85, 1719-1726.
47. Ferone, D., Van Hagen, P.M., Pivonello, R., Colao, A., Lamberts, S.W.J. & Hofland, L.J. (2000a) Physiological and pathophysiological role of somatostatin receptors in the human thymus. European Journal of Endocrinology, 143, S27-S34.
48. Ferone, D., Van Hagen, P.M., Van Koetsveld, P.M., Zuiderwijk, J., Mooy, D.M., Lichtenauer-Kaligis, E.G., Colao, A., Bogers, A.J., Lombardi, G., Lamberts, S.W. & Hofland, L.J. (1999) In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology, 140, 373-380.
49. Ferrara, N. & Bunting, S. (1996) Vascular endothelial growth factor, a specific regulator of angiogenesis. Current Opinion in Nephrology and Hypertension, 5, 35-44.
50. Florio, T., Yao, H., Carey, K.D., Dillon, T.J. & Stork, P.J. (1999) Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Molecular Endocrinology, 13, 24-37.
51. Folkman, J. (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Annals of Surgery, 175, 409-416.
52. Folkman, J. (1989) What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute, 82, 4-6.
53. Folkman, J. (1993) Tumor angiogenesis. In Cancer Medicine (ed. J.F. Wolland), pp. 153-171. Lea and Febiger, Philadelphia.
54. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine, 1, 27-31.
55. Folkman, J. & Shing, Y. (1992) Angiogenesis. Journal of Biological Chemistry, 267, 10931-10934.
56. Fontanini, G., Vignati, S., Pacini, F., Pollina, L. & Basolo, F. (1996) Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Modern Pathology, 9, 636-641.
57. Gasparini, G. & Harris, A.L. (1995) Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. Journal of Clinical Oncology, 13, 765-782.
58. Gimbrone, M.A. Jr, Leapman, S.B., Cotran, R.S. & Folkman, J. (1972) Tumor dormancy in vitro by prevention of neovascularization. Journal of Experimental Medicine, 136, 261-276.
59. Gimbrone, M.A. Jr, Leapman, S.B., Cotran, R.S. & Folkman, J. (1973) Tumor angiogenesis: iris neovascularization at a distance from experimental intraocular tumors. Journal of the National Cancer Institute, 50, 219-228.
60. Grant, M.B., Caballero, S. & Millard, W.J. (1993a) Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regulatory Peptides, 48, 267-278.
61. Grant, M.B., Guay, C. & Marsh, R. (1990) Insulin-like growth factor I stimulates proliferation, migration, and plasminogen activator release by human retinal pigment epithelial cells. Current Eye Research, 9, 323-335.
62. Grant, M., Jerdan, J. & Merimee, T.J. (1987) Insulin-like growth factor-I modulates endothelial cell chemotaxis. Journal of Clinical Endocrinology and Metabolism, 65, 370-371.
63. Grant, M.B., Mames, R.N., Fitzgerald, C., Ellis, E.A., Aboufriekha, M. & Guy, C.J. (1993b) Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia, 36, 282-291.
64. Grant, M., Russell, B., Fitzgerald, C. & Merimee, T.J. (1986) Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes, 35, 416-420.
65. Gronbaek, H., Nielsen, B., Flyvbjerg, A. & Orskov, H. (1997a) Effect of graded renal ablation on kidney and serum insulin-like growth factor-I (IGF-I) and IGF binding proteins in rat: relation to compensatory renal growth. Metabolism: Clinical and Experimental, 46, 29-35.
66. Gronbaek, H., Volmers, P., Bjorn, S.F., Osterby, R., Orskov, H. & Flyvbjerg, A. (1997b) Effect of GH/IGF-I deficiency on long-term renal changes and urinary albumin excretion in diabetic dwarf rats. American Journal of Physiology, 272, 918-924.
67. Guidi, A.J., Abu-Jawdeh, G., Tognazzi, K., Dvorak, H.F. & Brown, L.F. (1996) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer, 78, 454-460.
68. Gulec, S.A., Drouant, G.J., Fuselier, J., Anthony, C.T., De Heneghan, J.I., Carpio, J.B., Coy, D.H., Murphy, W.A. & Woltering, E.A. (2001) Anti-tumor and antiangiogenic effects of somatostatin receptor-targeted in situ radiation with (111)In-DTPA-JIC 2DL. Journal of Surgical Research, 97, 131-137.
69. Gyr, K.E. & Meier, R. (1993) Pharmacodynamic effects of Sandostatin in the gastrointestinal tract. Digestion, 54 (Suppl. 1), 14-19.
70. Hanahan, D. & Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
71. Hayry, P., Aavik, E. & Myllarniemi, M. (1996) Blockade of growth factor synthesis and growth factor action: two possible sites of interference in allograft vessel disease and coronary bypass or balloon injury. Metabolism, 45 (Suppl. 1), 101-103.
72. Helboe, L. & Moller, M. (1999) Immunohistochemical localization of somatostatin receptor subtypes sst1 and sst2 in the rat retina. Investigative Ophthalmology and Visual Science, 40, 2376-2382.
73. Hellstrom, A., Perruzzi, C., Ju, M., Engstrom, E., Hard, A., Liu, J., Albertsson-Wikland, K., Carlsson, B., Niklasson, A., Sjodell, L., LeRoith, D., Senger, D.R. & Smith, L.E.H. (2001) Low IGF-I suppress VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proceedings of the National Academy of Sciences of the United States of America, 98, 5804-5808.
74. Herrmann, G., Schumm-Draeger, P.M., Muller, C., Atai, E., Wenzel, B., Fabian, T., Usadel, K.H. & Hubner, K. (1994) T lymphocytes, CD68-positive cells and vascularisation in thyroid carcinomas. Journal of Cancer Research and Clinical Oncology, 120, 651-656.
75. Horak, E.R., Leek, R., Klenk, N., LeJeune, S., Smith, K., Stuart, N., Greenall, M., Stepniewska, K. & Harris, A.L. (1992) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet, 340, 1120-1124.
76. Hovind, P., Tarnow, L., Oestergaard, P.B. & Parving, H.H. (2000) Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney International, 57 (Suppl.), 75S56-61.
77. Hoyer, D., Bell, G.I., Berelowitz, M., Epelbaum, J., Feniuk, W., Humprey, P.P.A., O'Carroll, A.M., Patel, Y.C., Schonbrunn, A. & Taylor, J.E. (1995) Classification and nomenclature of somatostatin receptors. Trends in Pharmacological Science, 16, 86-88.
78. Hunyady, B., Hipkin, R.W., Schonbrunn, A. & Mezey, E. (1997) Immunohistochemical localization of somatostatin receptor sst2A in the rat pancreas. Endocrinology, 138, 2632-2635.
79. Ishiwata, T., Iino, Y., Takei, H., Oyama, T. & Morishita, Y. (1998) Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncology Reports, 5, 1343-1348.
80. Janson, E.T., Stridsberg, M., Gobl, A., Westlin, J.E. & Oberg, K. (1998) Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Research, 58, 2375-2378.
81. Jaquet, P., Ouafik, L., Saveanu, A., Gunz, G., Fina, F., Dufour, H., Culler, M.D., Moreau, J.P. & Enjalbert, A. (1999) Quantitative and functional expression somatostatin receptor subtypes in human prolactinomas. Journal of Clinical Endocrinology and Metabolism, 84, 326d-3276.
82. Johnson, J., Wong, H., Walsh, J.H. & Brecha, N.C. (1998) Expression of the somatostatin subtype 2A receptor in the rabbit retina. Journal of Comparative Neurology, 393, 93-101.
83. Jones, C.R., Millar, J.A., Lawrie, C., Sumner, D.J. & Reid, J.L. (1984) Specific inhibition of aldosterone responses to endogenous and exogenous angiotensin II by somatostatin. Clinical Endocrinology, 21, 279-284.
84. Jugenburg, M., Kovacs, K., Stefaneanu, L. & Scheithauer, B.W. (1995) Vasculature in nontumorous hypophyses, pituitary adenomas and carcinomas: a quantitative morphologic study. Endocrine Pathology, 6, 115-124.
85. Karalis, K., Mastrorakos, G., Chrousos, G.P. & Tolis, G. (1994) Somatostatin analogues suppress the inflammatory reaction in vitro. Journal of Clinical Investigation, 93, 2000-2006.
86. Kikutsuji, T., Harada, M., Tashiro, S., Ii, S., Moritani, M., Yamaoka, T. & Itakura, M. (2000) Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers. Journal of Hepatobiliary Pancreatic Surgery, 7, 496-503.
87. Kim, N.H., Jung, H.H., Cha, D.R. & Choi, D.S. (2000) Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. Journal of Endocrinology, 165, 617-624.
88. Kimura, N., Schindler, M., Kasai, N. & Kimura, I. (2001) Immunohistochemical localization of somatostatin receptor type 2A in rat and human tissues. Endocrine Journal, 48, 95-102.
89. Kirkegaard, C., Norgaard, K., Snorgaard, O., Bek, T., Larsen, M. & Lund-Andersen, H. (1990) Effect of one year continuous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in type I (insulin-dependent) diabetes mellitus. Acta Endocrinologica (Copenhagen), 122, 766-772.
90. Kliffen, M., Sharma, H.S., Mooy, C.M., Kerkvliet, S. & Jong, P.T.V.M. (1997) Increased expression of angiogenic growth factors in age-related maculopathy. British Journal of Ophthalmology, 81, 154-162.
91. Klisovic, D.D., O'Dorisio, M.S., Katz, S.E., Sall, J.W., Balster, D., O'Dorisio, T.M., Craig, E. & Lubow, M. (2001) Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Investigative Ophthalmology and Visual Science, 42, 2193-2201.
92. Kohner, E.M., Hamilton, A.M., Joplin, G.F. & Fraser, T.R. (1976) Florid diabetic retinopathy and its response to treatment by photocoagulation or pituitary ablation. Diabetes, 25, 104-110.
93. Lambooij, A.C., Kuijpers, R.W.A.M., Van Lichtenauer-Kaligis, E.G.R., Kliffen, M., Baarsma, G.S., Van Hagen, P.M. & Mooy, C.M. (2000) Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration. Investigative Ophthalmology and Visual Science, 41, 2329-2335.
94. Landau, D., Segev, Y., Afargan, M., Silbergeld, A., Katchko, L., Podshyvalov, A. & Phillip, M. (2001) A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse. Kidney International, 60, 505-512.
95. Lawnicka, H., Stepien, H., Wyczolkowska, J., Kolago, B., Kunert-Radek, J. & Komorowski, J. (2000) Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochemical and Biophysical Research Communications, 268, 567-571.
96. Le Romancer, M., Reyl-Desmars, F., Cherifi, Y., Pigeon, C., Bottari, S., Meyer, O. & Lewin, M.J. (1994) The 86-kDa subunit of autoantigen Ku is a somatostatin receptor regulating protein phosphatase 2A activity. Journal of Biological Chemistry, 269, 17464-17468.
97. Lennard, C.M., Patel, A., Wilson, J., Reinhardt, B., Tuman, C., Fenton, C., Blair, E., Francis, G.L. & Tuttle, R.M. (2001) Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery, 129, 552-558.
98. Liebow, C., Reilly, C., Serrano, M. & Schally, A. (1989) Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proceedings of the National Academy of Sciences of the United States of America, 86, 2003-2007.
99. Liotta, L.A., Steeg, P.S. & Stetler-Stevenson, W.G. (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-336.
100. Liu, Q., Djuricin, G., Staren, E.D., Gattuso, P., Gould, V.E., Shen, J., Saclarides, T., Rubin, D.B. & Prinz, R.A. (1996) Tumor angiogenesis in pheochromocytomas and paragangliomas. Surgery, 120, 938-942.
101. Loos, U., Raptis, S., Birk, J., Escobar-Jimenez, F., Meyer, G., Rothenbuchner, G. & Pfeiffer, E.F. (1978) Inhibition of TSH-stimulated radioiodine turnover and release of T4 and T3 in vitro by somatostatin. Metabolism, 27 (Suppl. 1), 1269-1273.
102. Maeda, K., Chung, Y.S., Takatsuka, S., Ogawa, Y., Onoda, N., Sawada, T., Kato, Y., Nitta, A., Arimoto, Y. & Kondo, Y. (1995) Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. British Journal of Cancer, 72, 319-323.
103. Mallet, B., Vialettes, B., Haroche, S., Escoffier, P., Gastaut, P., Taubert, J.P. & Vague, P. (1992) Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabetes and Metabolism, 18, 438-444.
104. Mandarino, L., Stenner, D., Blanchard, W., Nissen, S., Gerich, J., Ling, N., Brazeau, P., Bohlen, P., Esch, F. & Guillemin, R. (1981) Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion. Nature, 291, 76-77.
105. McCombe, M., Lightman, S., Eckland, D.J., Hamilton, A.M. & Lightman, S. (1991) Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study. Eye, 5, 569-575.
106. Mentlein, R., Eichler, O., Forstreuter, F. & Held-Feindt, J. (2001) Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. International Journal of Cancer, 92, 545-550.
107. Meyer-Schwickerath, R., Pfeiffer, A., Blum, W.F., Freyberger, H., Klein, M., Losche, C., Rollmann, R. & Schatz, H. (1993) Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Journal of Clinical Investigation, 92, 2620-2625.
108. Mezey, E., Hunyady, B., Mitra, S., Hayes, E., Liu, Q., Schaeffer, J. & Schonbrunn, A. (1998) Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary. Endocrinology, 139, 414-419.
109. Mitra, S.W., Mezey, E., Hunyady, B., Chamberlain, L., Hayes, E., Foor, F., Wang, Y., Schonbrunn, A. & Schaeffer, J.M. (1999) Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta cells. Endocrinology, 140, 3790-3796.
110. Moinet, C., Contour-Galcera, M.O., Poitout, L., Morgan, B., Gordon, T., Roubert, P. & Thurieau, C. (2001) Novel non-peptide ligands for the somatostatin sst3 receptor. Bioorganic and Medicinal Chemistry Letters, 11, 991-995.
111. Moreau, J.P. (2001) Oral presentation. 7th International Pituitary Congress.
112. Mountokalakis, T. & Levy, M. (1985) Effect of a selective octapeptide analogue of somatostatin on renal water excretion in the dog. Metabolism, 34, 408-409.
113. Nickoloff, B.J., Mitra, R.S., Varani, J., Dixit, V.M. & Polverini, P.J. (1994) Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. American Journal of Pathology, 144, 820-828.
114. O'Carroll, A.M., Raynor, K., Lolait, S.J. & Reisine, T. (1994) Characterization of cloned human somatostatin receptor SSTR5. Molecular Pharmacology, 46, 291-298.
115. O'Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R. & Folkman, J. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell, 88, 277-285.
116. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H. & Folkman, J. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315-328.
117. Ohji, H., Sasagawa, I., Iciyanagi, O., Suzuki, Y. & Nakada, T. (2001) Tumour angiogenesis and Ki-67 expression in phaeochromocytoma. British Journal of Urology International, 87, 381-385.
118. Oppizzi, G., Cozzi, R., Dallabonzana, D., Orlandi, P., Benini, Z., Petroncini, M., Attanasio, R., Milella, M., Banfi, G. & Possa, M. (1998) Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors. Journal of Endocrinological Investigation, 21, 512-519.
119. Pan, M.G., Florio, T. & Stork, P.J.S. (1992) G protein activation of a hormone-stimulated phosphatase in human tumor cells. Science, 256, 1215-1217.
120. Papotti, M., Kumar, U., Volante, M., Pecchioni, C. & Patel, Y.C. (2001) Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clinical Endocrinology, 54, 641-649.
121. Patel, Y.C. (1999) Somatostatin and its receptor family. Frontiers in Neuroendocrinology, 20, 157-198.
122. Patel, P.C., Barrie, R., Hill, N., Landeck, S., Kurozawa, D. & Woltering, E.A. (1994) Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery, 116, 1148-1152.
123. Pawlikowski, M., Kunert-Radek, J., Grochal, M., Zielinski, K. & Kulig, A. (1997) The effect of somatostatin analog octreotide on diethylstilbestrol-induced prolactin secretion, cell proliferation and vascular changes in the rat anterior pituitary gland. Histology and Histopathology, 12, 991-994.
124. Pe'er, J., Shweiki, D., Itin, A., Hemo, I., Gnessin, H. & Keshet, E. (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Laboratory Investigation, 72, 638-645.
125. Perego, C., Lattuada, D., Casnici, C., Gatti, S., Orsenigo, R., Panagiotis, S., Franco, P. & Marelli, O. (1998) Evidence that SMS 201-995 enhances the immunosuppressive effect of FK506. International Journal of Immunopharmacology, 20, 479-490.
126. Plate, K.H., Breier, G., Weich, H.A., Mennel, H.D. & Risau, W. (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. International Journal of Cancer, 59, 520-529.
127. Poulsen, J.E. (1953) The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond's disease. Diabetes, 2, 7-12.
128. Pradayrol, L., Jornvall, H., Mutt, V. & Ribet, A. (1980) N-terminally extended somatostatin: the primary structure of somatostatin-28. FEBS Letters, 109, 55-58.
129. Reardon, D.B., Dent, P., Wood, S.L., Kong, T. & Sturgill, T.W. (1997) Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Molecular Endocrinology, 11, 1062-1069.
130. Reichlin, S. (1983) Somatostatin. New England Journal of Medicine, 309, 1495-1563.
131. Reubi, J.C. (1985) A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinologica (Copenhagen), 109, 108-114.
132. Reubi, J.C., Horisberger, U. & Laissue, J. (1994) High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? International Journal of Cancer, 56, 681-688.
133. Reubi, J.C. & Laissue, J.A. (1995) Multiple actions of somatostatin in neoplastic disease. Trends in Pharmacological Science, 16, 110-115.
134. Reubi, J.C., Schaer, J.C., Waser, B., Hoeger, C. & Rivier, J. (1998) A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors. European Journal of Pharmacology, 345, 103-110.
135. Reubi, J.C., Waser, B., Foekens, J.A., Klijn, J.G., Lamberts, S.W.J. & Laissue, J. (1992) Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship of EGF receptor. International Journal of Cancer, 46, 416-420.
136. Reubi, J.C., Waser, B., Schaer, J.C. & Laissue, J.A. (2001) Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. European Journal of Nuclear Medicine, 28, 836-846.
137. Role, L.W., Leeman, S.E. & Perlman, R.L. (1981) Somatostatin and substance P inhibit catecholamine secretion from isolated cells of guinea-pig adrenal medulla. Neuroscience, 6, 1813-1821.
138. Rosenthal, J., Escobar-Jimenez, F. & Raptis, S. (1977) Prevention by somatostatin of rise in blood pressure and plasma renin mediated by beta-receptor stimulation. Clinical Endocrinology, 6, 455-462.
139. Sasano, H., Ohashi, Y., Suzuki, T. & Nagura, H. (1998) Vascularity in human adrenal cortex. Modern Pathology, 11, 329-333.
140. Schally, A.V. (1988) Oncological applications of somatostatin analogues. Cancer Research, 48, 6977-6985.
141. Schechter, J. (1972) Ultrastructural changes in the capillary bed of human pituitary tumors. American Journal of Pathology, 67, 109-126.
142. Schultz, G.S. & Grant, M.B. (1991) Neovascular growth factors. Eye, 5, 170-180.
143. Schulz, S., Shulz, S., Schmitt, J., Wiborny, D., Schmidt, H., Olbricht, S., Weise, W., Roessner, A., Gramsch, C. & Hollt, V. (1998) Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clinical Cancer Research, 4, 2047-2052.
144. Segal, K., Shpitzer, T., Feinmesser, M., Stern, Y. & Feinmesser, R. (1996) Angiogenesis in follicular tumors of the thyroid. Journal of Surgical Oncology, 63, 95-98.
145. Segev, Y., Landau, D., Marbach, M., Shehadeh, N., Flyvbjerg, A. & Phillip, M. (1997) Renal hypertophy in hyperglycemic non-obese diabetic mice is associated with persistent renal accumulation of insulin-like growth factor I. Journal of the American Society of Nephrology, 8, 436-444.
146. Sharp, P.S. (1995) The role of growth factors in the development of diabetic retinopathy. Metabolism: Clinical and Experimental, 44 (Suppl. 4), 72-75.
147. Shumak, S.L., Grossman, L.D., Chew, E., Kozousek, V., George, S.R., Singer, W., Harris, A.G. & Zinman, B. (1990) Growth hormone suppression
148. Sieber, C.C., Mosca, P.G. & Groszman, R.J. (1992) Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. American Journal of Physiology, 262, G274-G277.
149. Smith, L.E.H., Kopchick, J.J., Chen, W., Knapp, J., Kinose, F., Daley, D., Foley, E., Smith, R.H. & Schaeffer, J.M. (1997) Essential role of growth hormone in ischemia-induced retinal neovascularization. Science, 276, 1706-1709.
150. Spier, A.D. & de Lecea, L. (2000) Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Research Reviews, 33, 228-241.
151. Spranger, J., Buhnen, J., Jansen, V., Krieg, M., Meyer-Schwickerath, R., Blum, W.F., Schatz, H. & Pfeiffer, A.F. (2000) Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 (correction of IGF-BP3) in proliferative diabetic retinopathy. Hormone and Metabolic Research, 32, 196-200.
152. Sreedharan, S.P., Kodama, K.T., Peterson, K.E. & Goetzl, E.J. (1989) Distinct subsets of somatostatin receptors on cultured human lymphocytes. Journal of Biological Chemistry, 264, 949-952.
153. Srikant, C.B. & Patel, Y.C. (1981a) Somatostatin receptors: identification and characterization in rat brain membranes. Proceedings of the National Academy of Science of the United States of America, 78, 3930-3934.
154. Srikant, C.B. & Patel, Y.C. (1981b) Receptor binding of somatostatin-28 is tissue specific. Nature, 294, 259-260.
155. Suich, D.J., Mousa, S.A., Singh, G., Liapakis, G., Reisine, T. & DeGrado, W.F. (2000) Template-constrained cyclic peptide analogues of somatostatin: subtype-selective binding to somatostatin receptors and antiangiogenic activity. Bioorganic and Medicinal Chemistry, 8, 2229-2241.
156. Tolentino, M.J., Miller, J.W., Gragoudas, E.S., Chatzistefanou, K., Ferrara, N. & Adamis, A.P. (1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Archives of Ophthalmology, 114, 964-970.
157. Turman, M.A., O'Dorisio, M.S., O'Dorisio, T.M., Apple, C.A. & Albers, A.R. (1997) Somatostatin expression in human renal cortex and mesangial cells. Regulatory Peptides, 68, 15-21.
158. Turner, H.E., Nagy, Z., Esiri, M.M., Harris, A.L. & Wass, J.A.H. (2000a) Role of matrix metalloproteinase 9 in pituitary tumor behavior. Journal of Clinical Endocrinology and Metabolism, 85, 2931-2935.
159. Turner, H.E., Nagy, Z., Gatter, K.C., Esiri, M.M., Harris, A.L. & Wass, J.A.H. (2000b) Angiogenesis in pituitary adenomas and the normal pituitary gland. Journal of Clinical Endocrinology and Metabolism, 85, 1159-1162.
160. Turner, H.E., Nagy, Z., Gatter, K.C., Esiri, M.M., Harris, A.L. & Wass, J.A.H. (2000c) Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. Journal of Endocrinology, 165, 475-481.
161. Usenmez, T., Yildiz, O., Oktenlic, C., Ozgurtas, T. & Kutlu, M. (2000) Octreotide administration in diabetic rats: effects on renal function and morphology. Journal of Diabetes and its Complications, 14, 53-59.
162. Vale, W., Rivier, C., Brazeau, P. & Guillemin, R. (1974) Effects of somatostatin on the secretion of thyrotropin and prolactin. Endocrinology, 95, 968-977.
163. Van Eijck, C.H., Krenning, E.P., Bootsma, A., Oei, H.Y., Van Pel, R., Lindemans, J., Jeekel, J., Reubi, J.C. & Lamberts, S.W. (1994) Somatostatin receptor scintigraphy in primary breast cancer. Lancet, 343, 640-643.
164. Vidal, S., Kovacs, K., Horvath, E., Scheithauer, B.W., Kuroki, T. & Lloyd, R.V. (2001) Microvessel density in pituitary adenomas and carcinomas. Virchows Archives, 438, 595-602.
165. Watson, J.C., Alperin-Lea, R.C., Redman, J.G., Gebhardt, B.M. & Woltering, E.A. (1996) Sst2 gene expression appears during human angiogenesis. Regulatory Peptides, 64, 206.
166. Watson, J.C., Balster, D.A., Gebhardt, B.M., O'Dorisio, T.M., O'Dorisio, M.S., Espenan, G.D., Drouant, G.J. & Woltering, E.A. (2001) Growing vascular endothelial cells express somatostatin subtype 2 receptors. British Journal of Cancer, 85, 266-272.
167. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E.N., Moore, D.H., Meli, S. & Gasparini, G. (1992) Tumour angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. Journal of the National Cancer Institute, 84, 1875-1887.
168. Weidner, N., Semple, J.P., Welch, W.R. & Folkman, J. (1991) Tumour angiogenesis and metastasis: correlation in invasive breast carcinoma. New England Journal of Medicine, 324, 1-8.
169. Weinstock, J.V. & Elliot, D. (1998) The substance P and somatostatin interferon-gamma immunoregulatory circuit. Annals of the New York Academy of Sciences, 840, 532-539.
170. Weiss, R.E., Reddi, A.H. & Nimni, M.E. (1981) Somatostatin can locally inhibit proliferation and differentiation of cartilage and bone precursor cells. Calcified Tissue International, 33, 425-430.
171. Wiedermann, C.J., Reinisch, N. & Braunsteiner, H. (1993) Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. Blood, 82, 954-960.
172. Woltering, E.A., Barrie, R., O'Dorisio, T.M., Arce, D., Ure, T., Cramer, A., Holmes, D., Robertson, J. & Fassler, J. (1991) Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. Journal of Surgical Research, 50, 245-251.
173. Woltering, E.A., Watson, J.C., Alperin-Lea, R.C., Sharma, C., Keenan, E., Kurozawa, D. & Barrie, R. (1997) Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Investigational New Drugs, 15, 77-86.
174. Xu, Y., Song, J., Bruno, J.F. & Berelowitz, M. (1993) Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4. Biochemical and Biophysical Research Communications, 193, 648-652.
175. Yamada, Y., Post, S.R., Wang, K., Tager, H.S., Bell, G.I. & Seino, S. (1992) Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proceedings of the National Academy of Sciences of United States of America, 89, 251-255.
176. Yasuda, K., Rens-Domiano, S., Breder, C.D., Law, S.F., Saper, C.B., Reisine, T. & Bell, G.I. (1992) Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylcyclase. Journal of Biological Chemistry, 267, 20422-20428.
177. Yoshiji, H., Kuriyama, S., Kawata, M., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H. & Fukui, H. (2001) The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumour growth and angiogenesis: possible role of the vascular endothelial growth factor. Clinical Cancer Research, 7, 1073-1078.